1. Sansone, VA, Burge, J, McDermott, MP, Smith, PC, Herr, B, Tawil, R et al.. Randomized, placebo-controlled trials of dichlorphenamide in periodic paralysis. Neurology. 2016;86 (15):1408-16. doi: 10.1212/WNL.0000000000002416. PubMed PMID:26865514 PubMed Central PMC4831040.
  2. Sengupta, M, Cheema, A, Kaminski, HJ, Kusner, LL, Muscle Study Group. Serum metabolomic response of myasthenia gravis patients to chronic prednisone treatment. PLoS ONE. 2014;9 (7):e102635. doi: 10.1371/journal.pone.0102635. PubMed PMID:25032816 PubMed Central PMC4102553.
  3. Sanders, DB, Burns, TM, Cutter, GR, Massey, JM, Juel, VC, Hobson-Webb, L et al.. Does change in acetylcholine receptor antibody level correlate with clinical change in myasthenia gravis?. Muscle Nerve. 2014;49 (4):483-6. doi: 10.1002/mus.23944. PubMed PMID:23835683 .
  4. Lewis, RA, McDermott, MP, Herrmann, DN, Hoke, A, Clawson, LL, Siskind, C et al.. High-dosage ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A: results of a randomized, double-masked, controlled trial. JAMA Neurol. 2013;70 (8):981-7. doi: 10.1001/jamaneurol.2013.3178. PubMed PMID:23797954 PubMed Central PMC3752369.
  5. Pasnoor, M, He, J, Herbelin, L, Dimachkie, M, Barohn, RJ, Muscle Study Group et al.. Phase II trial of methotrexate in myasthenia gravis. Ann. N. Y. Acad. Sci. 2012;1275 :23-8. doi: 10.1111/j.1749-6632.2012.06804.x. PubMed PMID:23278574 PubMed Central PMC3564221.
  6. Rose, MR, Sadjadi, R, Weinman, J, Akhtar, T, Pandya, S, Kissel, JT et al.. Role of disease severity, illness perceptions, and mood on quality of life in muscle disease. Muscle Nerve. 2012;46 (3):351-9. doi: 10.1002/mus.23320. PubMed PMID:22907225 .
  7. Sadjadi, R, Vincent, KA, Carr, AJ, Walburn, J, Brooks, VL, Pandya, S et al.. Validation of the individualised neuromuscular quality of life for the USA with comparison of the impact of muscle disease on those living in USA versus UK. Health Qual Life Outcomes. 2011;9 :114. doi: 10.1186/1477-7525-9-114. PubMed PMID:22177525 PubMed Central PMC3295649.
  8. Muscle Study Group. A randomized, pilot trial of etanercept in dermatomyositis. Ann. Neurol. 2011;70 (3):427-36. doi: 10.1002/ana.22477. PubMed PMID:21688301 PubMed Central PMC3170432.
  9. Kaufmann, P, McDermott, MP, Darras, BT, Finkel, R, Kang, P, Oskoui, M et al.. Observational study of spinal muscular atrophy type 2 and 3: functional outcomes over 1 year. Arch. Neurol. 2011;68 (6):779-86. doi: 10.1001/archneurol.2010.373. PubMed PMID:21320981 PubMed Central PMC3839315.
  10. Sadjadi, R, Rose, MR, Muscle Study Group. What determines quality of life in inclusion body myositis?. J. Neurol. Neurosurg. Psychiatr. 2010;81 (10):1164-6. doi: 10.1136/jnnp.2009.183863. PubMed PMID:20601666 .
  11. Jackson, CE, Gronseth, G, Rosenfeld, J, Barohn, RJ, Dubinsky, R, Simpson, CB et al.. Randomized double-blind study of botulinum toxin type B for sialorrhea in ALS patients. Muscle Nerve. 2009;39 (2):137-43. doi: 10.1002/mus.21213. PubMed PMID:19145653 .
  12. Burns, TM, Conaway, MR, Cutter, GR, Sanders, DB, Muscle Study Group. Construction of an efficient evaluative instrument for myasthenia gravis: the MG composite. Muscle Nerve. 2008;38 (6):1553-62. doi: 10.1002/mus.21185. PubMed PMID:19016543 .
  13. Wolfe, GI, Barohn, RJ, Sanders, DB, McDermott, MP, Muscle Study Group. Comparison of outcome measures from a trial of mycophenolate mofetil in myasthenia gravis. Muscle Nerve. 2008;38 (5):1429-33. doi: 10.1002/mus.21142. PubMed PMID:18949779 .
  14. Mullins, LL, Carpentier, MY, Paul, RH, Sanders, DB, Muscle Study Group. Disease-specific measure of quality of life for myasthenia gravis. Muscle Nerve. 2008;38 (2):947-56. doi: 10.1002/mus.21016. PubMed PMID:18697209 .
  15. Burns, TM, Conaway, MR, Cutter, GR, Sanders, DB, Muscle Study Group. Less is more, or almost as much: a 15-item quality-of-life instrument for myasthenia gravis. Muscle Nerve. 2008;38 (2):957-63. doi: 10.1002/mus.21053. PubMed PMID:18642357 .
  16. Vernino, S, Lindstrom, J, Hopkins, S, Wang, Z, Low, PA, Muscle Study Group et al.. Characterization of ganglionic acetylcholine receptor autoantibodies. J. Neuroimmunol. 2008;197 (1):63-9. doi: 10.1016/j.jneuroim.2008.03.017. PubMed PMID:18485491 PubMed Central PMC2536520.
  17. Muscle Study Group. A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology. 2008;71 (6):394-9. doi: 10.1212/01.wnl.0000312373.67493.7f. PubMed PMID:18434639 .
  18. Jackson, CE, Barohn, RJ, Gronseth, G, Pandya, S, Herbelin, L, Muscle Study Group et al.. Inclusion body myositis functional rating scale: a reliable and valid measure of disease severity. Muscle Nerve. 2008;37 (4):473-6. doi: 10.1002/mus.20958. PubMed PMID:18236463 .
  19. Muscle Study Group. Randomized pilot trial of high-dose betaINF-1a in patients with inclusion body myositis. Neurology. 2004;63 (4):718-20. . PubMed PMID:15326251 .
  20. Muscle Study Group. Randomized pilot trial of betaINF1a (Avonex) in patients with inclusion body myositis. Neurology. 2001;57 (9):1566-70. . PubMed PMID:11706093 .

Abstracts

  1. Burns TM, Conaway M, Sanders DB, Muscle Study Group. Correlation of quality-of-life with regional symptoms and signs in MG: Muscle Study Group CellCept trial experience. Ann NY Acad Sci 2008; 1132:369-370.
  2. Massey JM, Sanders DB, Saperstein DS, Barohn RJ, Meriggioli MN, Nations SP, Muscle Study Group. Comparison of single fiber EMG studies to outcome measures in a controlled study of mycophenolate mofetil in generalized MG. Ann NY Acad Sci 2008; 1132:377.